Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (March 2026)
26 slides from Invo Fertility's investor presentation, March 2026
Slide 1: Life Begins Within – March 2026 Corporate Presentation
L IF E B E G IN S W IT H IN M A R C H 2 0 2 6 C O R P O R A T E P R E S E N TA T IO N N A S D A Q : IV F
Slide 2: Forward-Looking Statements
NASDAQ: IVF F O R W A R D -LO O K IN G S T A T E M E N T S This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this presentation t
Slide 3: Our Mission
O U R M IS S IO N We are a specialty healthcare company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient- centered approach that is powered by innovation, compassion and an exceptional team. 3
Slide 4: Key Highlights: Results, Operating Focus & Market Trends
NASDAQ: IVF K E Y H IG H L IG H T S R E S U LT S , O P E R A T IN G F O C U S & MARKET TRENDS R E V E N U E G R O W T H ($ M illio ns) R e ve nue G ro w th $7 • Driven by fertility services, including M&A strategy $6.5 M o m e ntum B uild ing To w ard B re ake ve n $6 $5.3 • Adjusted EBITDA1 loss re
Slide 5: Company Evolution: Expanding Our Focus in the Fertility Market
NASDAQ: IVF C O M PA N Y E V O LU T IO N E X PA N D IN G O U R F O C U S IN T H E F E R T IL IT Y M A R K E T Beyond our device heritage to a comprehensive healthcare provider + Need different image – to say Fertility center – rather than invocenter Pro p rie tary and no ve l inno vative m e d ic al
Slide 6: U.S. IVF Market: Scale, Growth + Consolidation Tailwinds
NASDAQ: IVF F E R T IL IT Y M a rke t Estimated ART Clinics by Ownerships 3 U .S . IV F M A R K E T : SC A LE, G RO W TH + C O N S O L ID A T IO N T A ILW IN D S 114 • M arke t siz e & g ro w th (U .S . IV F ) 1 (2 0 2 3 ) 197 • ~$ 5 .7 B • E st 5 .1 % C A G R (2 0 2 4 –2 0 3 0 ) • C linic land sc a
Slide 7: Fertility Centers
NASDAQ: IVF ` F E R T IL IT Y C E N T E R S
Slide 8: Fertility Centers + Cycles Across 4 Fertility Centers
NASDAQ: IVF F E R T IL IT Y C E N T E R S 1 0 0 0 + C Y C L E S IN 2 0 2 5 A C R O S S 4 F E R T IL IT Y C E N T E R S LO C A T IO N Middleton, WI Atlanta, GA Birmingham, AL Indianapolis, IN1 PRO C E D U RE S IVF, IVC planned IVC, IVF planned IVF and IVC IVF and IVC A N N U A L C Y C LE S ~500 ~150
Slide 9: Clinic Revenue Growth
NASDAQ: IVF REVENUE G RO W TH C LIN IC R E V E N U E * $8.0 $7.7 $7.0 $6.1 $6.0 $5.0 $4.3 $ Millions $4.0 $3.0 $2.0 $1.7 $1.0 $0.0 2022 2023 2024 YTD Q3 2025 *Revenue inc lud e s b o th consolidated revenue from Wisconsin Fertility and Atlanta INVO Center, as well as revenue from Birmingham, which i
Slide 10: Mission and Growth Strategy
NASDAQ: IVF M IS S IO N A N D G R O W T H S T R A T E G Y B E C O M E A L E A D IN G P R O V ID E R O F F E R T IL IT Y S E R V IC E S A N D T E C H N O LO G Y A c q uisitio ns b ring ac c e le rate d b ulk to o p e ratio ns and faste r p athw ay to o ve rall p ro fitab ility. Setting the company up
Slide 11: Wisconsin Fertility Institute – M&A Strategy Case Study
NASDAQ: IVF CASE STUDY – M&A STRATEGY W IS C O N S IN F E R T IL IT Y IN S T IT U T E A c q uisitio n D e tails • One of Wisconsin’s leading fertility centers (rated top-100 in US by Newsweek) • 5,000+ babies born since 2007, averaging 500+ IVF cycles/year over the last 5 years • Strong team in plac
Slide 12: Bloom Fertility – New-Build Clinic Case Study
NASDAQ: IVF C A S E S T U D Y – N E W -B U IL D C L IN IC B LO O M F E R T IL IT Y C linic D e tails • INVO Center focused primarily on IVC procedure • Approximately 500 IVC cycles since 2022, averaging around 150 cycles/year • Seasoned team in place G ro w th D e tails • Add IVF and hire new doctor
Slide 13: Why Join INVO Fertility?
NASDAQ: IVF ADVAN TAG ES W H Y J O IN IN V O F E R T IL IT Y ? L ike -M ind e d Partne rs; S yne rg ie s • Focus on medical practice and patient services, while INVO corporate provides centralized administration, finance, marketing, human resources and other services • Strength in unity – generate s
Slide 14: Technology
N A S D A Q : IV F T E C H N O LO G Y
Slide 15: Leveraging Technology to Expand Access
NASDAQ: IVF L E V E R A G IN G T E C H N O LO G Y T O E X PA N D A C C E S S M e d ic al d e vic e he ritag e Unique INVOcell-enabled IVC procedure improves lab efficiency and capacity, increases fertility service supply and helps to reduce the risk of mix-up occurrences, while providing a more conn
Slide 16: INVOcell: Unique Product, Revolutionary Procedure
NASDAQ: IVF IN V O c e ll® U N IQ U E P R O D U C T , R E V O LU T IO N A R Y P R O C E D U R E For clinical pregnancy rates, INVOcell outcomes are comparable to IVF and more effective than IUI. A D VA N C E D T RE AT M E N T IU I IN V O c e ll (IV C ) IV F 8-10%* ~57.1%** ~51.8%** SUCCESS SUCCESS S
Slide 17: Financials
N A S D A Q : IV F F I N A N C IA L S
Slide 18: Income Statement Highlights
NASDAQ: IVF IN C O M E S T A T E M E N T H IG H L IG H T S (USD) FY 2022 FY 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Clinic 614,854 2,862,574 1,537,199 1,807,921 1,418,011 1,687,300 6,450,431 1,621,553 1,832,094 1,722,223 Product 207,342 158,001 39,087 28,676 15,140 -1,33
Slide 19: Balance Sheet Highlights
NASDAQ: IVF B A L A N C E S H E E T H IG H L IG H T S (USD) 12/31/2023 12/31/2024 9/30/2025 Cash and cash equivalents 232,424 619,520 355,891 Other current assets 1,027,351 698,811 780,914 Lease right of use 5,740,929 2,283,784 2,096,739 Intangible assets 4,093,431 3,275,931 1,430,495 Goodwill 5,878
Slide 20: Key Information: Stock Data
NASDAQ: IVF STO CK DATA K E Y IN F O R M A T IO N INVO Fertility (Nasdaq: IVF) Data as of 3/3/26* Market capitalization $6.9 million Stock price $0.86 Common shares issued and outstanding 8,077,095 Warrants Outstanding (Avg. $2.71, 9.4 mil @ $1.59) 9,537,821 45,526 Options, etc Outstanding (Avg. $11
Slide 21: Summary
O)INVvO kertiity NASDAQ: IVF SUMMARY
Slide 22: Why Invest in INVO Fertility? Key Takeaways
N A S D A Q : IV F W H Y IN V E S T IN IN V O F E R T IL IT Y ? KEY TA KEA W AY S G ro w ing C linic M & A Fo c us to D rive Inte g ratio n o f U niq ue Ind ustry M o m e ntum B uild ing O p e ratio ns A d d e d G ro w th Te c hno lo g ie s Tailw ind s To w ard s B re ake ve n • 4 current fully • Pr
Slide 23: People
N A S D A Q : IV F PE O PLE
Slide 24: Experienced & Dedicated Leadership Team
NASDAQ: IVF L E A D E R S H IP T E A M E X P E R IE N C E D & D E D IC A T E D D o c to rs S te ve S hum CEO G re tc he n C o llins S ue E lle n C a rp e nte r N ic k C ata ld o Ja m e s D o na hue 1 A nd re a G o re n Te ra h K rig svo ld M&A/Legal Finance/Accounting L a b D ire c to rs A p ril M c
Slide 25: Board of Directors
NASDAQ: IVF B O A R D O F D IR E C T O R S IN D E P E N D E N T & E N G A G E D S te ve S hum Tre nt D avis R e b e c c a M e ssina B arb ara R yan M atthe w S z o t CEO, Director Independent Director Independent Director Independent Director Independent Director March 2026 © 2026 INVO Fertility, In
Slide 26: Thank You
THANK YO U Fo r m o re info rm atio n, p le ase c o ntac t: Steve Shum Andrea Goren 978-878-9505 x506 978-878-9505 x520 sshum@invofertility.com agoren@invofertility.com